Guardant Health, founded in 2012 and headquartered in Palo Alto, California, is a precision oncology company that develops blood-based tests for cancer screening, detection, and treatment selection. Its work centres on liquid biopsy technology, which analyses circulating tumour DNA from a standard blood draw rather than requiring tissue samples. The company operates CLIA-certified, CAP-accredited laboratories and maintains a presence across the Americas, Europe, Asia, the Middle East, and Africa.
The firm's product portfolio includes several firsts in the field. Shield became the first FDA-approved blood test for primary colorectal cancer screening, intended for adults aged 45 and older at average risk. Guardant360 CDx was the first FDA-approved blood test for comprehensive genomic profiling in advanced cancer management. Guardant Reveal is designed for early-stage cancer detection. To date, the company has performed over 500,000 blood tests, with approximately 12,000 physicians using its diagnostics.
Beyond clinical diagnostics, Guardant Health works in real-world evidence generation and genomic profiling, serving both oncology patients and the biopharmaceutical industry. Its stated mission is to conquer cancer with data, and it applies rigorous quality standards across its laboratory operations.
